DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
AT A GLANCE | COMPANY NEWS | COMPANY WEBSITE | SEC FILINGS | STOCK QUOTE
Companies To Watch
XXII 1.39 +0.01 CKPT 10.25 +0.00 CPHR 2.9901 +0.0000 CFRX 1.40 -0.10 CRBP 6.45 -0.30 DMPI 2.20 -0.10 DVAX 5.70 +0.15 FBIO 3.95 +0.11 KERX 6.46 +0.04 MTNB 3.00 -0.03 MDGN 5.57 +0.17 MNOV 5.95 -0.10 MTFB 8.99 +0.59 PRQR 5.00 +0.05 STML 8.45 +0.10 SYN 0.6068 +0.0148 TGTX 12.05 +0.15 THLD 0.4693 +0.0093 TNXP 4.46 +0.11 VSTM 2.37 +0.00 ZIOP 6.29 -0.28 2017-05-26 16:01
- Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
- Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
- Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol